All holdings
Pacific Biosciences Calif PACB
Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them
Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance
Share price change by quarter +24.1% Q3 ’24
+7.6% Q4 ’24
-35.5% Q1 ’25
+5.1% Q2 ’25
+3.2% Q3 ’25
+46.1% Q4 ’25
-29.4% Q1 ’26
+27.3% Q2 ’26
Q3 ’24: +24.1%; Q4 ’24: +7.6%; Q1 ’25: -35.5%; Q2 ’25: +5.1%; Q3 ’25: +3.2%; Q4 ’25: +46.1%; Q1 ’26: -29.4%; Q2 ’26: +27.3% Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.
Managers holding it, by quarter 1 Q4 ’23
1 Q1 ’24
1 Q2 ’24
1 Q3 ’24
1 Q4 ’24
1 Q1 ’25
1 Q2 ’25
1 Q3 ’25
2 Q4 ’25
1 Q1 ’26
1 Q2 ’26
0 Q3 ’26
Q4 ’23: 1; Q1 ’24: 1; Q2 ’24: 1; Q3 ’24: 1; Q4 ’24: 1; Q1 ’25: 1; Q2 ’25: 1; Q3 ’25: 1; Q4 ’25: 2; Q1 ’26: 1; Q2 ’26: 1; Q3 ’26: 0 Counts the managers on this site whose 13F for that quarter includes Pacific Biosciences Calif.
Who holds it Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.
Managers holding Pacific Biosciences Calif Manager Portfolio▼ Value Change Held for Horizon Kinetics 0.0%$17k $17k ▼ Trimmed -4.6%30 qtrs
Download the holders: CSV · JSON · Markdown
Directors buying and selling Open-market trades by directors, officers and 10% holders over the last 12 months. How this works From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Sort by Date (high to low) Date (low to high) Who (Z–A) Who (A–Z) Shares (high to low) Shares (low to high) Value (high to low) Value (low to high) Insider purchases and sales of Pacific Biosciences Calif Date▼ Who Bought or sold Shares Price Value Filing 6 Oct 2026 Gibson James R IISee Remarks ▼ Sold 661,815 $3.11 $2.1m Form 4 17 Aug 2026 Van Oene MarkSee Remarks ▼ Sold 26,911 $1.13 $30k Form 4
About the company Sector Technology · Laboratory Analytical Instruments Incorporated in Delaware Financial year ends 31 December Shares outstanding 311m at 31 Jul 2026 SEC filings Annual reports and other filings on EDGAR Revenue and profit $28.2m 2013
$92.8m 2015
$93.5m 2017
2019
2021
2023
2025
2013: $28.2m; 2014: $60.6m; 2015: $92.8m; 2016: $90.7m; 2017: $93.5m; 2018: $78.6m; 2019: not held; 2020: not held; 2021: not held; 2022: not held; 2023: not held; 2024: not held; 2025: not held Pacific Biosciences Calif revenue and net income by year Year Revenue Net income 2025 – −$546m 2024 – −$310m 2023 – −$307m 2022 – −$314m 2021 – −$181m 2020 – $29.4m 2019 – −$84.1m 2018 $78.6m −$103m 2017 $93.5m −$92.2m 2016 $90.7m −$74.4m 2015 $92.8m −$31.7m 2014 $60.6m −$66.2m 2013 $28.2m −$79.3m
From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.